EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis

Alessandro Malara, Cristian Gruppi, Vittorio Abbonante, Daniele Cattaneo, Luigi De Marco, Margherita Massa, Alessandra Iurlo, Umberto Gianelli, Carlo L. Balduini, Maria E. Tira, Andrès F. Muro, Anil K. Chauhan, Vittorio Rosti, Giovanni Barosi, Alessandra Balduini

Research output: Contribution to journalArticle

Abstract

The fibronectin EDA isoform (EDA FN) is instrumental in fibrogenesis but, to date, its expression and function in bone marrow (BM) fibrosis have not been explored. We found that mice constitutively expressing the EDA domain (EIIIA+/+), but not EDA knockout mice, are more prone to develop BM fibrosis upon treatment with the thrombopoietin (TPO) mimetic romiplostim (TPOhigh). Mechanistically, EDA FN binds to TLR4 and sustains progenitor cell proliferation and megakaryopoiesis in a TPO-independent fashion, inducing LPS-like responses, such as NF-κB activation and release of profibrotic IL-6. Pharmacological inhibition of TLR4 or TLR4 deletion in TPOhigh mice abrogated Mk hyperplasia, BM fibrosis, IL-6 release, extramedullary hematopoiesis, and splenomegaly. Finally, developing a novel ELISA assay, we analyzed samples from patients affected by primary myelofibrosis (PMF), a well-known pathological situation caused by altered TPO signaling, and found that the EDA FN is increased in plasma and BM biopsies of PMF patients as compared with healthy controls, correlating with fibrotic phase.

Original languageEnglish
Pages (from-to)587-604
Number of pages18
JournalThe Journal of experimental medicine
Volume216
Issue number3
DOIs
Publication statusPublished - Mar 4 2019

Fingerprint

Primary Myelofibrosis
Megakaryocytes
Fibronectins
Thrombopoietin
Inflammation
Interleukin-6
Extramedullary Hematopoiesis
Splenomegaly
Knockout Mice
Hyperplasia
Protein Isoforms
Stem Cells
Bone Marrow
Enzyme-Linked Immunosorbent Assay
Cell Proliferation
Pharmacology
Biopsy
human extra domain A fibronectin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis. / Malara, Alessandro; Gruppi, Cristian; Abbonante, Vittorio; Cattaneo, Daniele; De Marco, Luigi; Massa, Margherita; Iurlo, Alessandra; Gianelli, Umberto; Balduini, Carlo L.; Tira, Maria E.; Muro, Andrès F.; Chauhan, Anil K.; Rosti, Vittorio; Barosi, Giovanni; Balduini, Alessandra.

In: The Journal of experimental medicine, Vol. 216, No. 3, 04.03.2019, p. 587-604.

Research output: Contribution to journalArticle

Malara, Alessandro ; Gruppi, Cristian ; Abbonante, Vittorio ; Cattaneo, Daniele ; De Marco, Luigi ; Massa, Margherita ; Iurlo, Alessandra ; Gianelli, Umberto ; Balduini, Carlo L. ; Tira, Maria E. ; Muro, Andrès F. ; Chauhan, Anil K. ; Rosti, Vittorio ; Barosi, Giovanni ; Balduini, Alessandra. / EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis. In: The Journal of experimental medicine. 2019 ; Vol. 216, No. 3. pp. 587-604.
@article{39edf23672694e2e9cb273bb6aee9ad8,
title = "EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis",
abstract = "The fibronectin EDA isoform (EDA FN) is instrumental in fibrogenesis but, to date, its expression and function in bone marrow (BM) fibrosis have not been explored. We found that mice constitutively expressing the EDA domain (EIIIA+/+), but not EDA knockout mice, are more prone to develop BM fibrosis upon treatment with the thrombopoietin (TPO) mimetic romiplostim (TPOhigh). Mechanistically, EDA FN binds to TLR4 and sustains progenitor cell proliferation and megakaryopoiesis in a TPO-independent fashion, inducing LPS-like responses, such as NF-κB activation and release of profibrotic IL-6. Pharmacological inhibition of TLR4 or TLR4 deletion in TPOhigh mice abrogated Mk hyperplasia, BM fibrosis, IL-6 release, extramedullary hematopoiesis, and splenomegaly. Finally, developing a novel ELISA assay, we analyzed samples from patients affected by primary myelofibrosis (PMF), a well-known pathological situation caused by altered TPO signaling, and found that the EDA FN is increased in plasma and BM biopsies of PMF patients as compared with healthy controls, correlating with fibrotic phase.",
author = "Alessandro Malara and Cristian Gruppi and Vittorio Abbonante and Daniele Cattaneo and {De Marco}, Luigi and Margherita Massa and Alessandra Iurlo and Umberto Gianelli and Balduini, {Carlo L.} and Tira, {Maria E.} and Muro, {Andr{\`e}s F.} and Chauhan, {Anil K.} and Vittorio Rosti and Giovanni Barosi and Alessandra Balduini",
year = "2019",
month = "3",
day = "4",
doi = "10.1084/jem.20181074",
language = "English",
volume = "216",
pages = "587--604",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "3",

}

TY - JOUR

T1 - EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis

AU - Malara, Alessandro

AU - Gruppi, Cristian

AU - Abbonante, Vittorio

AU - Cattaneo, Daniele

AU - De Marco, Luigi

AU - Massa, Margherita

AU - Iurlo, Alessandra

AU - Gianelli, Umberto

AU - Balduini, Carlo L.

AU - Tira, Maria E.

AU - Muro, Andrès F.

AU - Chauhan, Anil K.

AU - Rosti, Vittorio

AU - Barosi, Giovanni

AU - Balduini, Alessandra

PY - 2019/3/4

Y1 - 2019/3/4

N2 - The fibronectin EDA isoform (EDA FN) is instrumental in fibrogenesis but, to date, its expression and function in bone marrow (BM) fibrosis have not been explored. We found that mice constitutively expressing the EDA domain (EIIIA+/+), but not EDA knockout mice, are more prone to develop BM fibrosis upon treatment with the thrombopoietin (TPO) mimetic romiplostim (TPOhigh). Mechanistically, EDA FN binds to TLR4 and sustains progenitor cell proliferation and megakaryopoiesis in a TPO-independent fashion, inducing LPS-like responses, such as NF-κB activation and release of profibrotic IL-6. Pharmacological inhibition of TLR4 or TLR4 deletion in TPOhigh mice abrogated Mk hyperplasia, BM fibrosis, IL-6 release, extramedullary hematopoiesis, and splenomegaly. Finally, developing a novel ELISA assay, we analyzed samples from patients affected by primary myelofibrosis (PMF), a well-known pathological situation caused by altered TPO signaling, and found that the EDA FN is increased in plasma and BM biopsies of PMF patients as compared with healthy controls, correlating with fibrotic phase.

AB - The fibronectin EDA isoform (EDA FN) is instrumental in fibrogenesis but, to date, its expression and function in bone marrow (BM) fibrosis have not been explored. We found that mice constitutively expressing the EDA domain (EIIIA+/+), but not EDA knockout mice, are more prone to develop BM fibrosis upon treatment with the thrombopoietin (TPO) mimetic romiplostim (TPOhigh). Mechanistically, EDA FN binds to TLR4 and sustains progenitor cell proliferation and megakaryopoiesis in a TPO-independent fashion, inducing LPS-like responses, such as NF-κB activation and release of profibrotic IL-6. Pharmacological inhibition of TLR4 or TLR4 deletion in TPOhigh mice abrogated Mk hyperplasia, BM fibrosis, IL-6 release, extramedullary hematopoiesis, and splenomegaly. Finally, developing a novel ELISA assay, we analyzed samples from patients affected by primary myelofibrosis (PMF), a well-known pathological situation caused by altered TPO signaling, and found that the EDA FN is increased in plasma and BM biopsies of PMF patients as compared with healthy controls, correlating with fibrotic phase.

UR - http://www.scopus.com/inward/record.url?scp=85062410600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062410600&partnerID=8YFLogxK

U2 - 10.1084/jem.20181074

DO - 10.1084/jem.20181074

M3 - Article

C2 - 30733282

AN - SCOPUS:85062410600

VL - 216

SP - 587

EP - 604

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 3

ER -